SCHEMBL7220823

SCHEMBL7220823

COC(=O)c1ccc(Oc2cccc3ccccc23)cc1NS(=O)(=O)Cc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.51
MAPK1 P28482 1/20 0.51
PTK2B Q14289 1/20 0.51
ACLY P53396 2/20 0.46
BCL2L1 Q07817 1/20 0.44
MCL1 Q07820 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MAPT P10636 2/20 0.43
HPGD P15428 2/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.42
GAA P10253 1/20 0.42
CARM1 Q86X55 1/20 0.41
PRMT6 Q96LA8 1/20 0.41
MEN1 O00255 2/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MITF O75030 1/20 0.41
POLB P06746 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
BRAF P15056 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7219476 0.78 MRGPRX1 (0.52) BCL2L1MCL1
SCHEMBL28945290 0.75 ESRRA (0.50) ALDH1A1MAPK1BCL2L1MCL1KDM4E
SCHEMBL2273163 0.75 ACLY (0.67) ALDH1A1MAPK1PTK2BACLYMCL1
SCHEMBL7227894 0.75 ALDH1A1 (0.54) ALDH1A1MAPK1PTK2BBCL2L1MCL1
SCHEMBL31615645 0.72 ALDH1A1 (0.62) ALDH1A1MAPK1PTK2BACLYKDM4E
SCHEMBL31616003 0.70 ACLY (0.53) ALDH1A1MAPK1PTK2BACLYKDM4E
SCHEMBL31615940 0.70 ALDH1A1 (0.50) ALDH1A1MAPK1PTK2BACLYKDM4E
SCHEMBL31615793 0.70 ALDH1A1 (0.59) ALDH1A1MAPK1PTK2BACLYKDM4E
SCHEMBL28028822 0.70 GLO1 (0.62) ALDH1A1MAPK1PTK2BACLYKDM4E
SCHEMBL27928487 0.69 POLB (0.64) BCL2L1MCL1KDM4EMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6573278-B2 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma BAYER AKTIENGESELLSCHAFT (DE) 2003-06-03 US disclosed
US-20020072529-A1 Arylsulfonamides and analogues BAYER INTELLECTUAL PROPERTY GMBH (DE) 2002-06-13 US disclosed
US-6262112-B1 1-(4,4,4-TRIFLUOROBUTYLSULPHONYLOXY)-3-(2-(HYDROXYMETHYL)INDAN -4-YLOXY)-BENZENE BAYER AKTIENGESELLSCHAFT (DE) 2001-07-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020072529-A1 Arylsulfonamides and analogues ARSA, PRSS12, SNCA ALDH1A1 3020/4885MAPK1 3238/4885PTK2B 2375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.